be effective in inhibiting virus-induced cytopathogenic effect. Against this virus, OCH3UdR was found to be as potent as 5-iododeoxyuridine and cytosine arabinoside. The a-anomer of OCH3UdR did not show antiviral activity. Preliminary toxicity studies indicate that OCH3UdR has a very low acute toxicity.
Several pyrimidine nucleosides have been shown to possess inhibitory activity against deoxyribonucleic acid (DNA) viruses (6, 17, 19) . 5-Iododeoxyuridine (IUdR) has been shown to be effective in the topical treatment of keratitis due to herpes simplex (9, 11) and vaccinia viruses (12) . Other thymidine antimetabolites such as cytosine arabinoside (ara-C) (2), 5-trifluoromethyl-2'-deoxyuridine (7, 10) , and 5-ethyl-2'-deoxyuridine (5) have also been reported to possess anti-herpes activity. The therapeutic value of nucleoside antimetabolites in the treatment of viral diseases has been diminished because of their lack of selective action (3, 5, 18) .
Bacteriophages have been shown to possess certain unique pyrimidines in their nucleic acids. 5-Hydroxymethyl-2'-deoxyuridylate and 5-hydroxymethyl-2'-deoxycyticylate have been shown to replace thymidylate in the DNA of bacteriophages lytic for Bacillus subtilis (8, 16) and Escherichia coli (4), respectively. Analogues of these unique pyrimidines (5-hydroxymethyldeoxyribonucleosides) would be particularly useful compounds if they were preferentially incorporated into viral DNA and thus were selectively virotoxic. In this communication, we report the antiviral properties of several ether derivatives of 5-hydroxymethyldeoxyuridine (OHUdR). (20) , and monolayers of BFK or DK cells were used for all viral chemotherapy experiments. RESULTS
The design of a primary antiviral chemotherapy experiment is shown in Fig. 1 and is a modification of the method of Sidwell and Huffman (21) . Each cup was seeded with 1 (1,960 and 19.6 ug/ml) was added to give the desired final concentration. These concentrations were selected because ara-C and IUdR exhibited marked antiviral activity at these levels. Serial log10 dilutions of each stock virus (titer, 106) were prepared in maintenance medium, and 25,uliters of the appropriate dilution of virus was added to the cups in each experiment. The plates were sealed with adhesive-backed clear acetate sealers, incubated at 37 C for 3 days, and then examined microscopically for cytopathogenic effect (CPE). CPE and cytotoxicity were graded on a scale of 0 (normal cells) to 4 (complete degeneration of the monolayer). The antiviral activity of each compound was determined by inhibition of CPE.
The cytotoxicity of each compound was assessed microscopically by comparing the toxicity controls (compound plus medium) with the cell controls (medium only) and the virus controls (virus plus medium). The drug control cells were scored as follows: increased granularity (1+), slight vacuolation (2+), large holes in the monolayer (3+), and destruction of the cell layer (4+). Any increase in these parameters in the toxicity controls was taken into account in determining the true antiviral effect (degree of inhibition of CPE) of each compound.
The relative antiviral potency of ether derivatives of OHUdR (structural formulas are shown in Fig. 2) , IUdR, and ara-C was determined by using secondary BFK cells against IBR virus, and the results of three identical experiments are summarized in Table 1 ). Similarly, at the higher concentration no difference in antiviral activity was observed when these drugs were added 18 h post-infection. However, at a concentration of 2.8 ,ug/ml, OCH3UdR was devoid of activity, whereas IUdR showed slight activity (0.5 log inhibition of CPE). In combination with IUdR or ara-C, OCH3UdR failed to show synergistic or additive activity when added 18 h before virus infection. In combination experiments, each compound was used at a final concentration of 280 ,g/ml.
Preliminary acute toxicity studies using Swiss mice (20 to 
